Log in to search using one of your social media accounts:

 

Why this $300 million biotech IPO could be huge — or another flop in Alzheimer’s and ALS

There's a lot riding on Denali Therapeutics Inc.'s upsized, mountainous $303 million IPO — and it goes beyond the eye-popping fundraise. To be sure, investors are watching the South San Francisco developer of drugs for Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis, or ALS — in a Securities and Exchange Commission filing Thursday morning, the 125-employe e company boosted the shares available in the IPO from 9.58 million to 15.97 million. At the top of its $17 to…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Abstract The evolutionarily conserved FOXO family of transcription factors has emerged as a significant arbiter of neural cell fate and function in mammals. From the neural stem cell (NSC) state through mature neurons under both physiological and pathological conditions, they have been found to modulate neural cell survival, stress responses, lineage commitment, and neuronal signaling. Lineage-specific FOXO knockout mice have provided an invaluable tool for the dissection of FOXO biology in the nervous system. Within the NSC compartments of the brain, FOXOs are required for the maintenance of NSC quiescence and fo...
Source: Current Topics in Developmental Biology - Category: Biology Authors: Tags: Curr Top Dev Biol Source Type: research
Publication date: Available online 6 February 2018 Source:Molecular Aspects of Medicine Author(s): Susmita Sil, Palsamy Periyasamy, Annadurai Thangaraj, Ernest T. Chivero, Shilpa Buch Platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) are expressed in several cell types including the brain cells such as neuronal progenitors, neurons, astrocytes, and oligodendrocytes. Emerging evidence shows that PDGF-mediated signaling regulates diverse functions in the central nervous system (CNS) such as neurogenesis, cell survival, synaptogenesis, modulation of ligand-gated ion channels, and development of specific ty...
Source: Molecular Aspects of Medicine - Category: Molecular Biology Source Type: research
Authors: Verde F, Del Tredici K, Braak H, Ludolph A Abstract Amyotrophic lateral sclerosis (ALS) is traditionally considered a disease affecting exclusively motor neurons. However, much evidence points towards additional involvement of brain systems other than the motor. As much as half of ALS patients display cognitive-behavioral disturbances. ALS shares with a considerable proportion of FTD cases the same neuropathological substrate, namely, inclusions of abnormally phosphorylated protein TDP-43 (pTDP-43). In analogy with pathological staging systems elaborated in the past decades for Alzheimer's disease (AD) and...
Source: Archives Italiennes de Biologie - Category: Neuroscience Tags: Arch Ital Biol Source Type: research
Publication date: August 2018 Source:Current Opinion in Behavioral Sciences, Volume 22 Author(s): Ratko Radakovic, Sharon Abrahams Apathy is a demotivation syndrome common in neurodegenerative diseases and is fundamentally multidimensional in nature. Different methodologies have been used to identify and quantify these dimensions, which has resulted in multifarious concepts, ranging in the number and characteristics of apathy subtypes. This has created an ambiguity over the fundamental substructure of apathy. Here we review the multidimensional concepts of apathy and demonstrate that overlapping elements exist, pointing t...
Source: Current Opinion in Behavioral Sciences - Category: Psychiatry & Psychology Source Type: research
In conclusion, the present study demonstrated that TIGIT is a prominent negative immune regulator involved in immunosenescence. This novel finding is highly significant, as targeting TIGIT might be an effective strategy to improve the immune response and decrease age-related comorbidities. Delivery of Extracellular Vesicles as a Potential Basis for Therapies https://www.fightaging.org/archives/2018/01/delivery-of-extracellular-vesicles-as-a-potential-basis-for-therapies/ Here I'll point out a readable open access review paper on the potential use of extracellular vesicles as a basis for therapy: harveste...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
(Arizona State University) Lab-grown human neurons will be used to develop and test treatments for devastating neurodegenerative diseases, particularly Alzheimer's disease, Parkinson's disease and Amyotrophic lateral sclerosis.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
This article is protected by copyright. All rights reserved.
Source: Journal of Neurochemistry - Category: Neuroscience Authors: Tags: Review Source Type: research
Abstract Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease and prion disease are not timely and effectively treated using conventional therapies. This emphasizes the need for alternative therapeutic approaches. In this respect, gene-based therapies have been adopted as potentially feasible alternative therapies, where the microRNA (miRNA) approach has experienced a great explosion in recent years. Because miRNAs have been shown to be implicated in the pathogenesis of several diseases including neurodegenerative diseases, they are intens...
Source: Current Gene Therapy - Category: Genetics & Stem Cells Authors: Tags: Curr Gene Ther Source Type: research
Nature Reviews Drug Discovery 17, 88 (2018). doi:10.1038/nrd.2017.271 In 2006, Genentech re-entered into the neuroscience fray by partnering with AC Immune to develop novel Alzheimer disease treatments. A year and half later, Morgan Sheng joined the biotech firm as Vice President of Neuroscience, and was tasked with putting together a plan to eke new drug candidates out of emerging science. Ten years on, the firm's neuroscience pipeline includes three Alzheimer drugs, one amyotrophic lateral sclerosis drug, one pain drug and a number of preclinical candidates. Sheng spoke with Asher Mullard about his continued faith i...
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Tags: News and Analysis Source Type: research
Focus on Neuro Diseases We now have the capability to provide cells of the central and peripheral nervous system from donors with Neuro diseases. These include cells from donors with ALS, AD, PD, and Brain Cancer Donors, to name a few.We have provided cells to virtually all the large Pharmas and many small and mid-size Bio-techs. We have worked with Novartis to gain 21-CFR compliance for cells that they are using for their eye diseases drug discovery programs.I am at your “beck and call” should you have interested in exploring specific capabilities further. You can e-mail or call me at 612-801-1007
Source: Neuromics - Category: Neuroscience Tags: 3-D Cell based Assays ALS Alzheimer ' s Disease Amyotrophic Lateral Sclerosis glioblastomas Parkinson Source Type: news
More News: ALS | Alzheimer's | Biotechnology | Health Management | Parkinson's Disease | Pharmaceuticals